Research programme: genetic suppressor elements - Aventis Pharma/PPD DiscoveryAlternative Names: Genetic suppressor elements research programme: Aventis Pharma/PPD Discovery
Latest Information Update: 04 Apr 2003
At a glance
- Originator Aventis; PPD Discovery
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 21 Nov 2000 Preclinical development for Cancer in USA (Unknown route)
- 21 Nov 2000 New profile